Use of IL-1 inhibitors and TNF antagonists, partially in combination with recombinant erythropoietins, for the treatment of anemia

Details for Australian Patent Application No. 2006228063 (hide)

Owner Amgen Inc.

Inventors McCabe, Dorothy; Coccia, Marco A.; Newmark, Richard; Kay, Jonathan

Agent Shelston IP

Pub. Number AU-B-2006228063

Parent 2002220178

Filing date 13 October 2006

Wipo publication date 2 November 2006

Acceptance publication date 11 June 2009

International Classifications

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61K 38/20 (2006.01) Medicinal preparations containing peptides - Interleukins

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Event Publications

2 November 2006 Application Open to Public Inspection

  Published as AU-B-2006228063

2 November 2006 Complete Application Filed

11 June 2009 Application Accepted

  Published as AU-B-2006228063

8 October 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006228064-Method for modulating macrophage activation

2006228062-Device, system and method for dualpath ophthalmic device